Denali Therapeutics Inc to Highlight ALS and FTD Development Programs Transcript

Oct 06, 2021 / 08:30PM GMT
Laura Hansen - Denali Therapeutics Inc. - VP of IR

Hello, and welcome to the Denali Therapeutics webinar highlighting our therapeutic programs addressing amyotrophic lateral sclerosis or ALS and frontotemporal dementia or FTD.

I am Laura Hansen, Vice President of Investor Relations, and I'd like to thank you for joining us today.

Please note that the press release we issued earlier today and the slide deck for this webinar are available in the investors section of our website, denalitherapeutics.com.

Before we get started, I'd like to note that the presentations given today and the responses to questions will contain forward-looking statements regarding Denali's future plans, business strategy, product candidates, planned preclinical studies and clinical trials, among other things. Such statements are subject to numerous important risks, uncertainties and assumptions. Should any of these risks or uncertainties materialize or should our assumptions prove to be incorrect, our actual results could differ materially from those forward-looking statements. These risks, uncertainties

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot